Impacts of treatments on recurrence and 28-year survival of ischemic stroke patients

Abstract Aspirin and nicametate are well-established therapies for preventing recurrence and mortality from stroke in patients diagnosed as ischemic stroke. However, their respective effects on the recurrence, making allowance for the duration of recurrence and death without the occurrence of recurr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ting-Ann Wang, Tzy-Haw Wu, Shin-Liang Pan, Hsiu-Hsi Chen, Sherry Yueh-Hsia Chiu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/8a1005643321428a972712b8e89881bc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8a1005643321428a972712b8e89881bc
record_format	dspace
spelling	oai:doaj.org-article:8a1005643321428a972712b8e89881bc2021-12-02T16:06:42ZImpacts of treatments on recurrence and 28-year survival of ischemic stroke patients10.1038/s41598-021-94757-62045-2322https://doaj.org/article/8a1005643321428a972712b8e89881bc2021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-94757-6https://doaj.org/toc/2045-2322Abstract Aspirin and nicametate are well-established therapies for preventing recurrence and mortality from stroke in patients diagnosed as ischemic stroke. However, their respective effects on the recurrence, making allowance for the duration of recurrence and death without the occurrence of recurrence, and long-term survival have not been well elucidated. We aimed to evaluate long-term effect of two kinds of treatment on cerebrovascular death among ischemic stroke patients with or without the recurrence of stroke. Data used in this study were derived from the cohort based on a multicenter randomized double-blind controlled trial during 1992 to 1995 with the enrollment of a total of 466 patients with first-time non-cardioembolic ischemic stroke who were randomly allocated to receive aspirin (n = 222) or nicametate (n = 244). The trial cohort was followed up over time to ascertain the date of recurrence within trial period and death until Sep of 2019. The time-dependent Cox regression model was used to estimate the long-term effects of two treatments on death from cerebrovascular disease with and without recurrence. A total of 49 patients experienced stroke recurrence and 89 cerebrovascular deaths was confirmed. Patients treated with nicametate were more likely, but non statistically significantly, to have recurrence (aHR: 1.73, 95% CI 0.96–3.13) as compared with those treated by aspirin. Nicametate reduced the risk of cerebrovascular death about 37% (aHR: 0.63, 95% CI 0.41–0.97) compared with aspirin. The aspirin group had a lower recurrence rate than the nicametate group even with recurrence after 1–2 years of follow-up of first stroke but the latter had significantly reduced death from cerebrovascular disease for nicametate group, which requires more research to verify.Ting-Ann WangTzy-Haw WuShin-Liang PanHsiu-Hsi ChenSherry Yueh-Hsia ChiuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Ting-Ann Wang Tzy-Haw Wu Shin-Liang Pan Hsiu-Hsi Chen Sherry Yueh-Hsia Chiu Impacts of treatments on recurrence and 28-year survival of ischemic stroke patients
description	Abstract Aspirin and nicametate are well-established therapies for preventing recurrence and mortality from stroke in patients diagnosed as ischemic stroke. However, their respective effects on the recurrence, making allowance for the duration of recurrence and death without the occurrence of recurrence, and long-term survival have not been well elucidated. We aimed to evaluate long-term effect of two kinds of treatment on cerebrovascular death among ischemic stroke patients with or without the recurrence of stroke. Data used in this study were derived from the cohort based on a multicenter randomized double-blind controlled trial during 1992 to 1995 with the enrollment of a total of 466 patients with first-time non-cardioembolic ischemic stroke who were randomly allocated to receive aspirin (n = 222) or nicametate (n = 244). The trial cohort was followed up over time to ascertain the date of recurrence within trial period and death until Sep of 2019. The time-dependent Cox regression model was used to estimate the long-term effects of two treatments on death from cerebrovascular disease with and without recurrence. A total of 49 patients experienced stroke recurrence and 89 cerebrovascular deaths was confirmed. Patients treated with nicametate were more likely, but non statistically significantly, to have recurrence (aHR: 1.73, 95% CI 0.96–3.13) as compared with those treated by aspirin. Nicametate reduced the risk of cerebrovascular death about 37% (aHR: 0.63, 95% CI 0.41–0.97) compared with aspirin. The aspirin group had a lower recurrence rate than the nicametate group even with recurrence after 1–2 years of follow-up of first stroke but the latter had significantly reduced death from cerebrovascular disease for nicametate group, which requires more research to verify.
format	article
author	Ting-Ann Wang Tzy-Haw Wu Shin-Liang Pan Hsiu-Hsi Chen Sherry Yueh-Hsia Chiu
author_facet	Ting-Ann Wang Tzy-Haw Wu Shin-Liang Pan Hsiu-Hsi Chen Sherry Yueh-Hsia Chiu
author_sort	Ting-Ann Wang
title	Impacts of treatments on recurrence and 28-year survival of ischemic stroke patients
title_short	Impacts of treatments on recurrence and 28-year survival of ischemic stroke patients
title_full	Impacts of treatments on recurrence and 28-year survival of ischemic stroke patients
title_fullStr	Impacts of treatments on recurrence and 28-year survival of ischemic stroke patients
title_full_unstemmed	Impacts of treatments on recurrence and 28-year survival of ischemic stroke patients
title_sort	impacts of treatments on recurrence and 28-year survival of ischemic stroke patients
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/8a1005643321428a972712b8e89881bc
work_keys_str_mv	AT tingannwang impactsoftreatmentsonrecurrenceand28yearsurvivalofischemicstrokepatients AT tzyhawwu impactsoftreatmentsonrecurrenceand28yearsurvivalofischemicstrokepatients AT shinliangpan impactsoftreatmentsonrecurrenceand28yearsurvivalofischemicstrokepatients AT hsiuhsichen impactsoftreatmentsonrecurrenceand28yearsurvivalofischemicstrokepatients AT sherryyuehhsiachiu impactsoftreatmentsonrecurrenceand28yearsurvivalofischemicstrokepatients
_version_	1718384912953769984

Impacts of treatments on recurrence and 28-year survival of ischemic stroke patients

Ejemplares similares